Viking Therapeutics, Inc.

Day range

$37.71 – $43.1

52-week

$24.78 – $43.15

Volume

14.92M

Market cap

4.86B

P/E

—

1M

+25.34%

YTD

+18.39%

1Y

+66.8%

Avg volume

2.84M

Beta

0.68

EPS

$-4.67

Dividend yield

0%

Target

$94.82

Street

strong buy

Profit margin

0%

Revenue

—

VKTX chart

About VKTX

Healthcare · Biotechnology · NasdaqCM · 65 employees

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.